Hsbc Holdings PLC Purchases 35,902 Shares of Ralliant Corporation $RAL

Hsbc Holdings PLC raised its position in shares of Ralliant Corporation (NYSE:RAL) by 230.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,500 shares of the company’s stock after purchasing an additional 35,902 shares during the quarter. Hsbc Holdings PLC’s holdings in Ralliant were worth $2,627,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Dodge & Cox raised its position in shares of Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after purchasing an additional 1,434,376 shares during the period. Viking Global Investors LP bought a new position in Ralliant in the 2nd quarter worth $257,200,000. Millennium Management LLC increased its stake in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after buying an additional 3,147,660 shares in the last quarter. State Street Corp purchased a new stake in Ralliant in the 2nd quarter worth $213,096,000. Finally, Invesco Ltd. raised its holdings in Ralliant by 4.9% during the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after acquiring an additional 187,898 shares during the period.

Ralliant Trading Up 0.1%

RAL stock opened at $72.24 on Monday. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The stock has a market capitalization of $8.09 billion and a price-to-earnings ratio of -6.60. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The firm’s fifty day simple moving average is $58.13 and its two-hundred day simple moving average is $51.25.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million during the quarter. The business’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Citigroup upped their price target on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Finally, Barclays boosted their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.